Literature DB >> 18337345

Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trials.

Elke S Bergmann-Leitner1, Elizabeth H Duncan, John Robert Burge, Michele Spring, Evelina Angov.   

Abstract

To date, no immune correlates for blood stage-specific immunity against Plasmodium falciparum malaria parasites have been identified. Growth and/or invasion inhibition assays using sera from Phase 2a/b trials will aid in determining whether correlations with protective immunity can be established for these assays. A major constraint in the ability to evaluate functional antibody activities from populations in endemic areas is the relatively limited availability of sufficient sample quantity. For this reason, we developed a miniaturized and high-throughput method to measure growth inhibitory activity by quantification of parasite lactate dehydrogenase (pLDH) in a 384-microtiter plate format. This culture method can be extended beyond the pLDH-based readout to other techniques commonly used to determine growth/invasion inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337345

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

Review 1.  Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

Authors:  Christopher J A Duncan; Adrian V S Hill; Ruth D Ellis
Journal:  Hum Vaccin Immunother       Date:  2012-04-20       Impact factor: 3.452

2.  Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.

Authors:  Philip Bejon; Jackie Cook; Elke Bergmann-Leitner; Ally Olotu; John Lusingu; Jedidah Mwacharo; Johan Vekemans; Patricia Njuguna; Amanda Leach; Marc Lievens; Sheetij Dutta; Lorenz von Seidlein; Barbara Savarese; Tonya Villafana; Martha M Lemnge; Joe Cohen; Kevin Marsh; Patrick H Corran; Evelina Angov; Eleanor M Riley; Chris J Drakeley
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

3.  Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming.

Authors:  Martha Sedegah; Michael R Hollingdale; Fouzia Farooq; Harini Ganeshan; Maria Belmonte; Jun Huang; Esteban Abot; Keith Limbach; Ilin Chuang; Cindy Tamminga; Judith E Epstein; Eileen Villasante
Journal:  Hum Vaccin Immunother       Date:  2015-08-20       Impact factor: 3.452

4.  Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Authors:  Nekoye Otsyula; Evelina Angov; Elke Bergmann-Leitner; Margaret Koech; Farhat Khan; Jason Bennett; Lucas Otieno; James Cummings; Ben Andagalu; Donna Tosh; John Waitumbi; Nancy Richie; Meng Shi; Lori Miller; Walter Otieno; Godfrey Allan Otieno; Lisa Ware; Brent House; Olivier Godeaux; Marie-Claude Dubois; Bernhards Ogutu; W Ripley Ballou; Lorraine Soisson; Carter Diggs; Joe Cohen; Mark Polhemus; D Gray Heppner; Christian F Ockenhouse; Michele D Spring
Journal:  Malar J       Date:  2013-01-23       Impact factor: 2.979

5.  Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Authors:  Elke S Bergmann-Leitner; Elizabeth H Duncan; Ryan M Mease; Evelina Angov
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

6.  Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults.

Authors:  Arlene E Dent; Elke S Bergmann-Leitner; Danny W Wilson; Daniel J Tisch; Rhonda Kimmel; John Vulule; Peter Odada Sumba; James G Beeson; Evelina Angov; Ann M Moormann; James W Kazura
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240

7.  Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Dapa A Diallo; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Alassane Dicko; Issaka Sagara; Mahamadou S Sissoko; Mounirou Baby; Mady Sissoko; Issa Diarra; Amadou Niangaly; Amagana Dolo; Modibo Daou; Sory I Diawara; D Gray Heppner; V Ann Stewart; Evelina Angov; Elke S Bergmann-Leitner; David E Lanar; Sheetij Dutta; Lorraine Soisson; Carter L Diggs; Amanda Leach; Alex Owusu; Marie-Claude Dubois; Joe Cohen; Jason N Nixon; Aric Gregson; Shannon L Takala; Kirsten E Lyke; Christopher V Plowe
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

8.  Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies.

Authors:  Elke S Bergmann-Leitner; Ryan M Mease; Elizabeth H Duncan; Farhat Khan; John Waitumbi; Evelina Angov
Journal:  Malar J       Date:  2008-07-14       Impact factor: 2.979

9.  Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.

Authors:  Jeffrey A Lyon; Evelina Angov; Michael P Fay; JoAnn S Sullivan; Autumn S Girourd; Sally J Robinson; Elke S Bergmann-Leitner; Elizabeth H Duncan; Christian A Darko; William E Collins; Carole A Long; John W Barnwell
Journal:  PLoS One       Date:  2008-07-30       Impact factor: 3.240

Review 10.  Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines.

Authors:  Susanne H Sheehy; Alexander D Douglas; Simon J Draper
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.